Immunoprecise Antibodies Ltd
XTSX:IPA

Watchlist Manager
Immunoprecise Antibodies Ltd Logo
Immunoprecise Antibodies Ltd
XTSX:IPA
Watchlist
Price: 6.5 CAD 0.78%
Market Cap: 161.4m CAD

Net Margin
Immunoprecise Antibodies Ltd

-90%
Current
-90%
Average
1.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-90%
=
Net Income
-17.1m
/
Revenue
19m

Net Margin Across Competitors

No Stocks Found

Immunoprecise Antibodies Ltd
Glance View

ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.

IPA Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-90%
=
Net Income
-17.1m
/
Revenue
19m
What is the Net Margin of Immunoprecise Antibodies Ltd?

Based on Immunoprecise Antibodies Ltd's most recent financial statements, the company has Net Margin of -90%.

Back to Top